Cannabinoids may provide a safe and effective treatment option for neurogenic lower urinary tract dysfunction.
This is according to a study published in the British Journal of Urology International (BJUI); it was published online by the U.S. National Institute of Health.
According to researchers, the study’s objective was; “To systematically review all available evidence on efficacy and safety of cannabinoids for treating neurogenic lower urinary tract dysfunction (NLUTD) in patients with multiple sclerosis (MS).”
The review was performed according to the; “Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.”
After screening 8469 articles, two randomized controlled trials and one open label study enrolling a total of 426 patients, were included.
“Cannabinoids relevantly decreased incontinence episodes in all three studies”, says researchers. “Pooling data showed mean difference in incontinence episodes per 24 hours to be -0.35 (95% confidence interval -0.46 to -0.24). Mild adverse events were frequent (38-100%), but only two patients (0.7%) reported a serious adverse event.”
The study concludes; “Preliminary data imply, that cannabinoids might be an effective and safe treatment option for NULTD in patients with MS.”
However, the study notes that :evidence base is poor and more high-quality, well-designed, adequately powered and sampled studies are urgently needed to reach definitive conclusions.”
Click here for the full text of the study. It was conducted by researchers at; the University of Zürich, Cantonal Hospital Lucern and Research Consultants, all in Switzerland, as well as; Sorbonne Universités in France and; the National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology in London.